Development of a registry for monitoring psychotropic drug prescriptions: Aims, methods and implications for ordinary practice and research

International Journal of Methods in Psychiatric Research

Volumn 14, Issue 3, 2005, Pages 151-157

  Barbui, Corrado ^a   Nosè, Michela ^a   Rambaldelli, Gianluca ^a   Bonetto, Chiara ^a   Levi, Deborah ^a   Patten, Scott B ^b   Tansella, Michele ^a   Amaddeo, Francesco ^c   Androne, Nicola ^c   Barlocco, Leone ^c   Bianco, Maria ^c   Celani, Daniela ^c   Cipriani, Andrea ^c   Colombo, Paola ^c   Giaroli, Giovanni ^c   Gregis, Manuela ^c   Grosso, Lucia ^c   Guarnier, Chiara ^c   Latino, Matilde ^c   Maggiolo, Davide ^c   Malvini, Lara ^c   Marsilio, Alessandra ^c   Migliarese, Giovanni ^c   Moretti, Francesca ^c   Nicoli, Micaela ^c   Perego, Gianandrea ^c   Pighi, Cristina ^c   Pucci, Cristina ^c   Salvi, Giovanni ^c   Stegagno, Marco ^c   Tentoni, Luigi ^c   Tosato, Sarah ^c   Tournikioti, Kalliopi ^c   Turchetti, Roberto ^c   Venturi, Chiara ^c   Versace, Amelia ^c   Vivenza, Valerio ^c   Zambello, Francesco ^c   more..

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF CALGARY   (Canada)

^c NONE

Author keywords

Epidemiology; Prescription databases; Psychotropic drugs

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUPHENAZINE; HALOPERIDOL; LONG ACTING DRUG; LORAZEPAM; PSYCHOTROPIC AGENT;

ACCURACY; ARTICLE; CLINICAL PRACTICE; CULTURAL FACTOR; DEMOGRAPHY; DRUG EFFICACY; DRUG INFORMATION; DRUG RESEARCH; DRUG USE; DRUG WITHDRAWAL; HEALTH CARE UTILIZATION; HUMAN; INDIVIDUALIZATION; ITALY; LONGITUDINAL STUDY; MEDICAL AUDIT; MENTAL HEALTH SERVICE; METHODOLOGY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; REGISTER; RISK BENEFIT ANALYSIS; SOCIAL ASPECT; SYMPTOMATOLOGY;

DRUG MONITORING; DRUG UTILIZATION; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; REGISTRIES;

EID: 20444465640     PISSN: 10498931     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpr.1     Document Type: Article

References (29)

1. Amaddeo F, Beecham J, Bonizzato P, Fenyo A, Tansella M, Knapp M. The use of a case register to evaluate the costs of psychiatric care. Acta Psychiatr Scand 1997; 95: 159-98.
2. Barbui C, Broglio E, Laia AC, D'Agostino S, Enrico F, Ferraro L, Fiorio E, Miletti F, Pietraru C, Poggio L, Tognoni G. Cross-sectional database analysis of antidepressant prescribing in Italy. J Clin Psychopharmacol 2003; 23: 31-4.
3. Barbui C, Ciuna A, Nosé M, Levi D, Patten S, Amaddeo F, Tansella M. The changing pattern of inpatient antipsychotic drug use in Italy. Journal of Clinical Psychopharmacology, 2004; 24: 659-61.
4. Barbui C, Ciuna A, Nosé M, Patten SB, Stegagno M, Burti L, Amaddeo F, Tansella M. Off-label and non-classical prescriptions of antipsychotic agents in ordinary inpatient practice. Acta Psychiatr Scand 2004; 109: 275-8.
5. Barbui C, Danese A, Guaiana G, Mapelli L, Miele L, Monzani E, Percudani M, on behalf of the Study group. Prescribing second-generation antipsychotics and the evolving standard of care in Italy. Pharmacopsychiatry 2002; 6: 239-43.
6. Barbui C, Guaiana G, Garattini S. Regulatory issues in Europe. J Clin Psychopharmacol 2001; 21: 545-8.
7. Barbui C, Tognoni G, Garattini S. Clinical databases of patients receiving antidepressants. The missing link between research and practice? J Affect Disord 2002; 70: 191-6.
8. Bergman U. Pharmacoepidemiology - from description to quality assessment. Norv J Epidemiol 2001; 11: 31-6.
9. Black N. High-quality clinical databases: breaking down barriers. Lancet 1999; 353: 1205-6.
10. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103-8.
11. Grasela T. Pharmacoepidemiology: a scientific basis for outcome research. Ann Pharmacother 1996; 30: 188-90.
12. Hennessy S, Bilker WB, Knauss JS, Kimmel SE, Margolis DJ, Morri MF, Reynolds RF, Glasser DB, Strom BL. Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol. Br J Clin Pharmacol 2004; 58: 81-7.
13. Hotopf M, Churchill R, Lewis G. The pragmatic randomised controlled trial in psychiatry. Br J Psychiatry 1999; 175: 217-23.
14. Inman W, Pearce G. Prescriber profile and post-marketing surveillance. Lancet 1993; 342: 658-61.
15. Jick H, Garcia Rodriguez LA, Pérez-Gutthann S. Principles of epidemiological research on adverse and beneficial drug effects. Lancet 1998; 352: 1767-70.
16. Jones G. Prescribing and taking medicines. Concordance is a fine theory but it is mostly not being practised. BMJ 2003; 327: 819.
17. Keitner GI, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry 2003; 64: 1091-3.
18. Laupacis A, Paterson M, Mamdani M, Rostom A, Anderson GM. Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach. CMAJ 2003; 169: 1167-70.
19. McMahon AD, MacDonald TM. Design issues for drug epidemiology. Br J Clin Pharmacol 2000; 50: 419-25.
20. Naber D, Pincus H. We do not practice what we investigate and we do not investigate what we practise. Curr Opin Psychiatry 2003; 16: 701-2.
21. Pietraru C, Barbui C, Poggio L, Tognoni G. Antidepressant drug prescribing in Italy, 2000: analysis of a general practice database. Eur J Clin Pharmacol 2001; 57: 605-9.
22. Posternak MA, Zimmerman M, Keitner GI, Miller IW. A re-evaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry 2002; 159: 191-200.
23. Rosholm JU, Andersen M, Gram LF. Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study. Eur J Clin Pharmacol 2001; 56: 923-9.
24. Sorensen HT, Johnsen SP, Norgard B. Methodological issues in using prescription and other databases in pharmacoepidemiology. Norv J Epidemiol 2001; 11: 13-18.
25. Tansella M, Amaddeo F, Burti L, Garzotto N, Ruggeri M. Community-based mental health care in Verona, Italy. In D Goldberg, G Thornicroft (eds) Mental Health in Our Future Cities. Hove: Psychology Press, pp. 239-62.
26. Tansella M, Burti L. Integrating evaluative research and community-based mental health care in Verona, Italy. Br J Psychiatry 2003; 183: 167-9.
27. Wang PS, Schneeweiss S, Avorn J. Recent developments in psychpharmacoepidemiology. Curr Opin Psychiatry 2003; 16: 719-24.
28. WHO Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo: WHO, 1996.
29. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159: 469-73.